AUTL logo

Autolus Therapeutics plc

AUTL
Healthcare|Biotechnology|GB
$1.28
+0.02 (+1.59%)
Tangible Book / Share
$0.21
Cash / Share
$0.76
Financing Filings (last 12 months)
8
Shelf registrations / offering prospectuses — latest Sep 22, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (7)

Sep 2027
Est. completion
P1Systemic Lupus Erythematosus
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
NCT06333483n=16
Nov 2027
Est. completion
P1Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518n=30
May 2028
Est. completion
P2Acute Lymphocytic Leukemia (ALL)
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
NCT07053059n=30
Aug 2028
Est. completion
P2Lupus Nephritis
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800n=35
Feb 2029
Est. completion
P2Acute Lymphoblastic Leukemia
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
NCT07400029n=40
Jun 2029
Est. completion
P1P2Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
NCT04404660n=153
Aug 2029
Est. completion
P1Progressive Multiple Sclerosis
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743n=24

Recent Press Releases

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Nov 4, 2026 · GlobeNewsWire
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2026 · GlobeNewsWire
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Oct 26, 2026 · GlobeNewsWire
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Oct 5, 2026 · GlobeNewsWire
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Sep 9, 2026 · GlobeNewsWire

SEC Filings (76)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 22, 2026EFFECTDocumentIndex
Sep 22, 2026424B3Offering prospectusDocumentIndex
Sep 15, 2026DEL AMDocumentIndex
Sep 14, 2026S-3Shelf registrationDocumentIndex
Aug 28, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Jun 29, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 5, 2026EFFECTDocumentIndex
May 5, 2026EFFECTDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Apr 16, 20268-KMaterial eventDocumentIndex
Apr 15, 2026DEL AMDocumentIndex
Apr 15, 2026DEL AMDocumentIndex
Apr 13, 2026S-3Shelf registrationDocumentIndex
Apr 13, 2026S-3Shelf registrationDocumentIndex
Apr 8, 20268-KMaterial eventDocumentIndex
Mar 27, 202610-KAnnual reportDocumentIndex
Mar 27, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 26, 2026424B3Offering prospectusDocumentIndex
Jan 26, 20268-KMaterial eventDocumentIndex
Jan 12, 2026424B3Offering prospectusDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 3, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Dec 2, 2025424B3Offering prospectusDocumentIndex
Dec 2, 20258-KMaterial eventDocumentIndex
Nov 18, 2025S-8Employee stock planDocumentIndex
Nov 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 12, 2025424B3Offering prospectusDocumentIndex